| |
|
|
|
IBC Life Sciences, The Renaissance Washington, DC Hotel * Washington, DC
November 11-12, 2004
IBC’s 3rd Annual Post-Translational Modifications conference continues its reputation of delivering proven strategies and techniques to exploit post-translational changes to improve your therapeutic protein and prevent costly delays caused by unwanted modifications. Experts from industry and academia will demonstrate the economic impact of identifying and characterizing post-translational modifications to improve the half-life and quality of biotherapeutics and to reduce immunogenicity. Register for one - attend both! IBC’s 3rd Annual Conference on Post-Translational Modifications is co-located with IBC’s 8th International Conference on Well Characterized Biologicals. This creates for you a rare opportunity to share perspectives and strategies with hundreds of leaders in the industry through track hopping, shared sessions, an interactive panel discussion, luncheons, and cocktail reception. Program updates are available online at www.IBCLifeSciences.com/PTM, or, call IBC at +1 508-616-5550.
|
|
|
|
|
|
|
|
Organized by:
|
|
IBC Life Sciences |
|
|
Invited Speakers:
|
|
Keynote Address
FDA Perspectives on Specifications for Monoclonal Antibodies
Steven Kozlowski, Ph.D., Acting Director, Division of Monoclonal Antibodies, Office of Pharmaceutical Sciences, CDER, FDA
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
-
|
|
|
|
|
|
|
|
Registration:
|
|
Online: www.IBCLifeSciences.com/PTM
Phone: 508-616-5550 x1004
Fax: 508-616-5522
E-mail: reg@ibcusa.com
|
|
|
E-mail:
|
|
reg@ibcusa.com
|
|
|
|
|
|
|
|
|